Swayampakula Ramakanth

Daina Graybosch

Justin Zelin

Bill Ling

Rajan Sharma

Ashiq Mubarack

Asseema Deng

Carly Kenselaar

Jingming Chen

Liisa Bayko

Yigal Nochomovitz

- Innate Pharma has refreshed its strategy to focus on three key assets: IPH4502, lacutamab, and monalizumab, and plans to **reduce its organization by 30%**.  **[0001598599_2208040_0]** 
- Lacutamab, targeting cutaneous T cell lymphoma (CTCL), has **Breakthrough Therapy Designation from the FDA** and is on an accelerated path to approval for Cesare syndrome, with an **expected accelerated approval in 2027** and full approval for Mycosis fungoides (MF) and Sezary syndrome in **2029**.  **[0001598599_2208040_0]** **[0001598599_2208040_1]** 
- New claims data suggests a **significantly larger initial commercial opportunity** for lacutamab, with potential revenue up to **€150 million in Cesare syndrome** and up to **€500 million combining SS and MF** as a second-line option, giving the company confidence to potentially pursue commercialization independently.  **[0001598599_2208040_20]** **[0001598599_2208040_25]** **[0001598599_2208040_26]** 
- The Phase III PACIFIC-nine study for monalizumab (in collaboration with AstraZeneca) has completed enrollment, with data expected in **2026**, potentially triggering **milestones up to €825 million**.  **[0001598599_2208040_1]**  Early efficacy and safety data for IPH4502's Phase I study are expected by the **end of 2025 or early 2026**.  **[0001598599_2208040_1]**

Innate Pharma Outlines Strategic Priorities and Pipeline Progress

- Innate Pharma S.A. will host an analyst and investor event on **October 28, 2025**, to provide clinical perspectives and a market outlook for **lacutamab**.  **[1598599_0001628280-25-045045_exhibit991-251014.htm:0]** 
- Lacutamab is Innate's lead proprietary product, which is progressing towards potential **accelerated approval in S\u00e9zary syndrome (SS)** based on existing long-term follow-up data from the Phase 2 TELLOMAK study.  **[1598599_0001628280-25-045045_exhibit991-251014.htm:0]** 
- The event will feature discussions on **strong TELLOMAK Phase 2 results**, new real-world data indicating a **larger eligible U.S. cutaneous T-cell lymphoma (CTCL) patient population**, and updates on the planned Phase 3 trial and commercial opportunity.  **[1598599_0001628280-25-045045_exhibit991-251014.htm:0]** 
- Lacutamab has received **Breakthrough Therapy Designation for SS**.  **[1598599_0001628280-25-045045_exhibit991-251014.htm:1]**

Innate Pharma to Host Analyst and Investor Event on Lacutamab

- Innate Pharma will host an analyst and investor event on **October 28, 2025**, dedicated to its lead proprietary product, **lacutamab**.  **[1598599_46c68d49a68e4924b5f43b0aa2b7bcdb_0]** 
- The event will focus on lacutamab's **clinical prospects and commercial potential**, including its progress towards potential **accelerated approval in Sézary syndrome** and the launch of a **confirmatory Phase 3 study**.  **[1598599_46c68d49a68e4924b5f43b0aa2b7bcdb_0]** 
- Presentations will include data from the **Phase 2 TELLOMAK trial** and an analysis of the eligible US patient population for cutaneous T-cell lymphomas (CTCL), which Innate Pharma indicates is **larger than public data suggests**.  **[1598599_46c68d49a68e4924b5f43b0aa2b7bcdb_0]** **[1598599_46c68d49a68e4924b5f43b0aa2b7bcdb_1]** 
- Lacutamab has received several key regulatory designations, including **Breakthrough Therapy status from the FDA** for Sézary syndrome, as well as Fast Track, PRIME, and Orphan Drug status.  **[1598599_46c68d49a68e4924b5f43b0aa2b7bcdb_2]**

- Innate Pharma will host an analyst and investor event on **October 28, 2025**, to discuss its lead proprietary product, **lacutamab**.  **[1598599_6c98329b495b471b9c5dc6782fe103cd_0]** 
- The event will provide clinical perspectives and market outlook for lacutamab, which is progressing towards potential **accelerated approval in Sézary syndrome** and confirmatory Phase 3 initiation.  **[1598599_6c98329b495b471b9c5dc6782fe103cd_0]** **[1598599_6c98329b495b471b9c5dc6782fe103cd_1]** 
- The program will feature Dr. Pierluigi Porcu discussing results from the **TELLOMAK Phase 2 trial** and Innate Pharma's management providing updates on the planned Phase 3 trial, regulatory pathway, and commercial opportunity.  **[1598599_6c98329b495b471b9c5dc6782fe103cd_0]** 
- Lacutamab has received several key regulatory designations, including **Breakthrough Therapy Designation for Sézary syndrome**, Fast Track, PRIME, and Orphan Drug designations.  **[1598599_6c98329b495b471b9c5dc6782fe103cd_2]**

- Innate Pharma is strategically refocusing its investments on three high-value clinical assets: **IPH4502, Lacutamab, and Monalizumab**, while streamlining its organization.  **[1598599_2146128_0]**  For H1 2025, the company reported **$4.9 million** in total revenue and held **$70.4 million** in cash, cash equivalents, and financial assets as of June 30, 2025, providing a cash runway until the **end of Q3 2026**.  **[1598599_2146128_6]** 
- **Lacutamab** received **FDA Breakthrough Therapy Designation** for relapsed or refractory S\u00e9zary syndrome, with a Phase 3 protocol nearing completion and potential for accelerated approval around **2027**.  **[1598599_2146128_2]** **[1598599_2146128_4]** **[1598599_2146128_5]**  New U.S. claims data indicate a larger market opportunity for S\u00e9zary syndrome and CTCL than previously estimated.  **[1598599_2146128_5]** 
- The **Monalizumab** Phase 3 PACIFIC-9 trial, partnered with AstraZeneca, is fully recruited and on track for primary completion in H1 2026, with data expected in **H2 2026**.  **[1598599_2146128_4]**  Innate Pharma is eligible for up to an additional **$825 million** in development and commercial milestones from this partnership.  **[1598599_2146128_5]** 
- The **IPH4502** Phase 1 study is progressing well, with enrollment expected to complete before the **end of Q1 2026** and preliminary safety and activity data anticipated in the **first half of 2026**.  **[1598599_2146128_2]**

Innate Pharma Announces Strategic Refocus and Clinical Pipeline Updates for Q2 2025

- Innate Pharma reported a **cash position of €70.4 million** as of June 30, 2025, with an anticipated cash runway until **end Q3-2026**.  **[1598599_0001598599-25-000077_exh_991masterprhyveninnate.htm:0]**  The company recorded a **net loss of €21.3 million** for the first half of 2025, a significant change from a net income of €24.8 million in the first half of 2024, and revenue decreased to **€4.9 million**.  **[1598599_0001598599-25-000077_exh_991masterprhyveninnate.htm:4]** 
- The company is implementing a strategic focus to prioritize its highest-value clinical assets (IPH4502, lacutamab, and monalizumab) and expects to **decrease staffing levels by about 30%** by the first half of 2026.  **[1598599_0001598599-25-000077_exh_991masterprhyveninnate.htm:0]** **[1598599_0001598599-25-000077_exh_991masterprhyveninnate.htm:3]** 
- Key pipeline advancements include **lacutamab receiving FDA Breakthrough Therapy Designation** in February 2025 and the **completion of enrollment for monalizumab's Phase 3 PACIFIC-9 trial**, with a high-level read-out expected in H2 2026.  **[1598599_0001598599-25-000077_exh_991masterprhyveninnate.htm:0]** **[1598599_0001598599-25-000077_exh_991masterprhyveninnate.htm:2]** 
- Sanofi made a **€15 million equity investment** in Innate Pharma in April 2025, and Innate Pharma regained the rights to IPH6101 in July 2025.  **[1598599_0001598599-25-000077_exh_991masterprhyveninnate.htm:0]** **[1598599_0001598599-25-000077_exh_991masterprhyveninnate.htm:2]** **[1598599_0001598599-25-000077_exh_991masterprhyveninnate.htm:3]**

Innate Pharma Reports First Half 2025 Financial Results and Strategic Restructuring

- Innate Pharma reported a **net loss of €21.3 million** for the first half of 2025, with **cash, cash equivalents, and financial assets totaling €70.4 million** as of June 30, 2025.  **[1598599_0001598599-25-000075_inpha-20250630_d2.htm:3]** **[1598599_0001598599-25-000075_inpha-20250630_d2.htm:4]** 
- The company received **Breakthrough Therapy Designation (BTD)** from the FDA for **lacutamab** on February 17, 2025, and initiated a **Phase 1 study for IPH4502** on January 27, 2025.  **[1598599_0001598599-25-000075_inpha-20250630_d2.htm:13]** **[1598599_0001598599-25-000075_inpha-20250630_d2.htm:20]** 
- Sanofi made a **€15 million investment** in new ordinary shares of Innate on April 24, 2025, and Innate will **regain rights to SAR’579/IPH6101 (CD123 ANKET)** on July 1, 2025, following the termination of the related 2016 agreement with Sanofi.  **[1598599_0001598599-25-000075_inpha-20250630_d2.htm:13]** **[1598599_0001598599-25-000075_inpha-20250630_d2.htm:14]** **[1598599_0001598599-25-000075_inpha-20250630_d2.htm:20]** 
- Innate Pharma plans to **reduce staffing levels by approximately 30%** through a redundancy plan, expected to be completed during the first half of 2026.  **[1598599_0001598599-25-000075_inpha-20250630_d2.htm:41]**

Innate Pharma (IPHA)